Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial
Kotfis et al., Pharmaceuticals, doi:10.3390/ph15020200
https://c19early.org/kotfis.html